磺达肝癸钠用于急性心肌梗死PCI术后的临床观察

Clinical evaluation of fondaparinux in acute myocardical infraction percutaneous transluminal coronary intervention

目的:观察分析磺达肝癸钠用于急性心肌梗死经皮冠状动脉介入术(PCI)术后临床治疗的优势及重要性。方法:选取2008年9月～2010年12月本院住院患者187例,将其随机分为对照组94例和治疗组93例,两组基础治疗相同。对照组除基础治疗外,给予依诺肝素1mg/kg,皮下注射,每12小时1次,连用7d。治疗组给予磺达肝癸钠2.5mg/d皮下注射,每24小时1次,连用7d。观察治疗30d内心脏事件发生情况。结果:治疗组全因死亡例数、再发心绞痛例数均较对照组减少(P<0.05),而再发心肌梗死例数、心脏性死亡例数两组差异无统计学意义。结论:磺达肝癸钠治疗急性心肌梗死PCI术后较依诺肝素安全有效。

Objective：To observe the clinical value and security of acute myocardical infraction percutaneous transluminal coronary intervention（PCI） by using fondaparinux.Methods：187 patients were selected and randomly divided into control group（94 cases） and treatment group（93 cases）.Besides the basic treatment,1 mg/kg enoxaparine was administrated to the control group subcutaneously every 12 hours for 7 days.The treatment group were given fondaparinux 2.5 mg per day subcutaneously for 7 days.Occurrences of cardiac disease were observed for 30 days.Results：Occurrences of death,angina of the treatment group were obviously less than the control group（P〈0.05）.No obvious difference of re-infarction,cardiac death was found in both groups.Conclusion：Fondaparinux is a safe and effective treatment for AMI percutaneous transluminal coronary intervention.